A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.
暂无分享,去创建一个
M. Fassan | L. Antonuzzo | L. Rimassa | V. Zagonel | A. Avallone | A. Orlandi | S. Cascinu | V. Formica | M. Di Maio | A. Sartore-Bianchi | S. Siena | F. Leone | F. Loupakis | D. Santini | M. Scartozzi | S. Lonardi | F. Morano | F. Pietrantonio | H. Prenen | G. Aprile | A. Spallanzani | C. Cremolini | L. Salvatore | C. Antoniotti | F. Negri | N. Pella | R. Moretto | M. Schirripa | L. Calvetti | E. dell'Aquila | E. Ongaro | P. Ziranu | P. Biason | F. Zustovich | G. Tomasello | Ilaria Depetris | M. Calegari | S. Di Donato | R. Intini | E. De Luca | F. Urbano | Pasquale Buonandi | Federica Buggin | A. Prete | E. Dell'aquila | F. Buggin | E. Dell'Aquila
[1] F. Cianchi,et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer , 2020, Translational oncology.
[2] F. Pontén,et al. CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup , 2020, Frontiers in Oncology.
[3] M. Fassan,et al. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer , 2020, Cancer Cell International.
[4] S. Cascinu,et al. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights , 2019, International journal of molecular sciences.
[5] A. Falcone,et al. BRAF mutant metastatic colorectal cancers: new arrows in our quiver. , 2019, Annals of translational medicine.
[6] R. Epstein,et al. Impact of Prognostic Discussions on the Patient-Physician Relationship: Prospective Cohort Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Gerlinger,et al. Treatment and Survival Outcome of BRAF‐Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case‐Control Study , 2017, Clinical colorectal cancer.
[8] M. Kendrick,et al. Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. , 2017, The oncologist.
[9] Jeffrey S. Morris,et al. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes , 2017, Clinical Cancer Research.
[10] M. Nichelatti,et al. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis , 2017, Clinical colorectal cancer.
[11] J. Pignon,et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] W. Scheithauer,et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. , 2017, European journal of cancer.
[13] S. Jaeger,et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. , 2017, Cancer discovery.
[14] L. Diaz,et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). , 2017 .
[15] P. Quirke,et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] C. Tournigand,et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.
[17] V. Heinemann,et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Sabine Tejpar,et al. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression , 2016, Clinical Cancer Research.
[19] Laura Ferrari,et al. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer , 2015, British Journal of Cancer.
[20] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[21] C. Atreya,et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Gibbs,et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Tu,et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.
[24] M. Rugge,et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.
[25] C. Brigand,et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer , 2015, British Journal of Cancer.
[26] I. Nagtegaal,et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.
[27] G. Fontanini,et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. , 2014, European journal of cancer.
[28] M. Kalady,et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta‐analysis , 2013, Colorectal Disease.
[29] P. Gibbs,et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.
[30] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[31] J. Barrett,et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Meyerhardt,et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.
[33] D. Sargent,et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[35] F. Izzo,et al. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.
[36] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .